Template:Receptor tyrosine kinase inhibitors
From WikiMD's Wellness Encyclopedia
Template loop detected: Template:Receptor tyrosine kinase inhibitors
| Name | Target | Indications | Notes |
|---|---|---|---|
| Imatinib | BCR-ABL | Chronic myeloid leukemia, Gastrointestinal stromal tumor | First approved RTK inhibitor |
| Erlotinib | EGFR | Non-small cell lung cancer, Pancreatic cancer | Used in combination with gemcitabine for pancreatic cancer |
| Sunitinib | VEGFR, PDGFR | Renal cell carcinoma, Gastrointestinal stromal tumor | Multi-targeted RTK inhibitor |
| Gefitinib | EGFR | Non-small cell lung cancer | First EGFR inhibitor approved |
| Sorafenib | VEGFR, RAF kinase | Hepatocellular carcinoma, Renal cell carcinoma | Also inhibits RAF kinases |
| Lapatinib | HER2/neu, EGFR | Breast cancer | Used in combination with capecitabine |
| Name | Target | Indications | Notes |
|---|---|---|---|
| Imatinib | BCR-ABL | Chronic myeloid leukemia, Gastrointestinal stromal tumor | First approved RTK inhibitor |
| Erlotinib | EGFR | Non-small cell lung cancer, Pancreatic cancer | Used in combination with gemcitabine for pancreatic cancer |
| Sunitinib | VEGFR, PDGFR | Renal cell carcinoma, Gastrointestinal stromal tumor | Multi-targeted RTK inhibitor |
| Gefitinib | EGFR | Non-small cell lung cancer | First EGFR inhibitor approved |
| Sorafenib | VEGFR, RAF kinase | Hepatocellular carcinoma, Renal cell carcinoma | Also inhibits RAF kinases |
| Lapatinib | HER2/neu, EGFR | Breast cancer | Used in combination with capecitabine |
